SupplySide Stage: CBD and cannabinoid medicine: A maturing market but still not legal
Listen in as three OG hempsters counsel what it takes to keep the faith — patents, bioavailability, testing, gummies, regenerative ag, GMPs, delta-8 — and other tips, tricks and lessons learned.
Unbelievably, it’s going on four years since the FDA held its first (and only) public hearing on the status of hemp CBD. While the industry has clamored for regulatory certainty, the FDA has given anything but. The result is a continuous gray area that has kept the big mainstream food and beverage players away, and many (most?) mom-and-pop supplement brands have withered on the vine. Still, the well-capitalized, quality-conscious, market-savvy players remain in it to win it. In this lightning round session, hear three OG hempsters counsel what it takes to keep the faith — patents, bioavailability, testing, gummies, regenerative ag, GMPs, delta-8 — and other tips, tricks and lessons learned.
About the Author
You May Also Like